2
Clinical Trials associated with KH-917在中国健康男性受试者中比较KH917注射液与拓咨®单次皮下注射给药的药代动力学和安全性的Ⅰ期临床试验
[Translation] Phase I clinical trial comparing the pharmacokinetics and safety of KH917 injection and TuoZhi® after single subcutaneous injection in healthy Chinese male subjects
主要目的:对比中国健康男性受试者单次皮下注射由北京康弘生物医药有限公司研发的KH917注射液(规格:80mg(1ml)/支)与持证商Eli Lilly and Company研发的拓咨®(规格:80 mg/mL)后的体内药代动力学特征。
次要目的:对比中国健康男性受试者单次皮下注射KH917注射液与拓咨®的安全性和免疫原性。
[Translation] Primary objective: To compare the in vivo pharmacokinetic characteristics of KH917 injection (specification: 80 mg (1 ml)/vial) developed by Beijing Kanghong Biopharmaceutical Co., Ltd. and TuoZhi® (specification: 80 mg/mL) developed by Eli Lilly and Company after a single subcutaneous injection in healthy Chinese male subjects.
Secondary objective: To compare the safety and immunogenicity of KH917 injection and TuoZhi® after a single subcutaneous injection in healthy Chinese male subjects.
在中国健康男性受试者中比较KH917注射液与拓咨®单次皮下注射给药的药代动力学和安全性临床试验
[Translation] A clinical trial comparing the pharmacokinetics and safety of KH917 injection and TuoZhi® in healthy Chinese male subjects after single subcutaneous injection
主要目的:对比中国健康男性受试者单次皮下注射由北京康弘生物医药有限公司研发的KH917注射液(规格:80mg(1ml)/支)与持证商Eli Lilly and Company 研发的拓咨®(规格:80 mg/mL)后的体内药代动力学特征。
次要目的:对比中国健康男性受试者单次皮下注射KH917注射液与拓咨®的安全性和免疫原性。
[Translation] Primary objective: To compare the in vivo pharmacokinetic characteristics of KH917 injection (specification: 80 mg (1 ml)/vial) developed by Beijing Kanghong Biopharmaceutical Co., Ltd. and TuoZhi® (specification: 80 mg/mL) developed by Eli Lilly and Company after a single subcutaneous injection in healthy Chinese male subjects.
Secondary objective: To compare the safety and immunogenicity of KH917 injection and TuoZhi® after a single subcutaneous injection in healthy Chinese male subjects.
100 Clinical Results associated with KH-917
100 Translational Medicine associated with KH-917
100 Patents (Medical) associated with KH-917
100 Deals associated with KH-917